Breaking News

Rentschler, Horizon Ink Cell Line Development Pact

The alliance aims to drive efficiencies in biotherapeutic manufacturing from early drug development through commercial manufacturing

By: Contract Pharma

Contract Pharma Staff

Rentschler Biopharma SE and Horizon Discovery have signed a commercial license agreement under which, Rentschler will use Horizon’s CHOSOURCE platform with its in-house process for cell line development for difficult-to-express proteins. Horizon’s gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cGMP-compliant cell line will complement Rentschler Biopharma’s existing service offering, providing a royalty-free alternative for the production of highly complex proteins....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters